118 related articles for article (PubMed ID: 32442541)
21. The Effect of Caspase 8, 9 Gene Polymorphisms on Non-Hodgkin Lymphoma Susceptibility and Clinical/Pathological Features.
Barati F; Bahari G; Asadi A; Nakhaee A; Hashemi SM; Taheri M; Hashemi M
Asian Pac J Cancer Prev; 2022 Dec; 23(12):4339-4346. PubMed ID: 36580018
[TBL] [Abstract][Full Text] [Related]
22. Caspase 8 and caspase 9 gene polymorphisms and susceptibility to gastric cancer.
Liamarkopoulos E; Gazouli M; Aravantinos G; Tzanakis N; Theodoropoulos G; Rizos S; Nikiteas N
Gastric Cancer; 2011 Oct; 14(4):317-21. PubMed ID: 21461653
[TBL] [Abstract][Full Text] [Related]
23. Association of caspase 8 promoter variants and haplotypes with the risk of breast cancer and its molecular profile in an Iranian population: A case-control study.
Bagherabad MB; Afzaljavan F; Vahednia E; Rivandi M; Vakili F; Sadr SSH; Shandiz FH; Pasdar A
J Cell Biochem; 2019 Oct; 120(10):16435-16444. PubMed ID: 31257627
[TBL] [Abstract][Full Text] [Related]
24. Bi-directional PCR allele-specific amplification (bi-PASA) for detection of caspase-8 -652 6N ins/del promoter polymorphism (rs3834129) in breast cancer.
Hashemi M; Eskandari-Nasab E; Fazaeli A; Rezaei H; Mashhadi MA; Arbabi F; Taheri M
Gene; 2012 Aug; 505(1):176-9. PubMed ID: 22659694
[TBL] [Abstract][Full Text] [Related]
25. CASP8 variants D302H and -652 6N ins/del do not influence the risk of colorectal cancer in the United Kingdom population.
Pittman AM; Broderick P; Sullivan K; Fielding S; Webb E; Penegar S; Tomlinson I; Houlston RS
Br J Cancer; 2008 Apr; 98(8):1434-6. PubMed ID: 18362937
[TBL] [Abstract][Full Text] [Related]
26. A six-nucleotide insertion-deletion polymorphism in the CASP8 promoter associated with risk and progression of bladder cancer.
Wang M; Zhang Z; Tian Y; Shao J; Zhang Z
Clin Cancer Res; 2009 Apr; 15(7):2567-72. PubMed ID: 19276244
[TBL] [Abstract][Full Text] [Related]
27. CASP8 (rs3834129) and CASP3 (rs4647601) polymorphisms in oropharynx cancer risk, tumor cell differentiation, and prognosis in a cohort of the Brazilian population.
Tortorelli GA; Torricelli C; Carron J; Costa EFD; Lopes-Aguiar L; Carvalho BF; Rinck-Junior JA; Mariano FV; Altemani AMAM; Lima CSP; Lourenço GJ
Mol Biol Rep; 2019 Dec; 46(6):6557-6563. PubMed ID: 31587185
[TBL] [Abstract][Full Text] [Related]
28. Functional variants in cell death pathway genes and risk of pancreatic cancer.
Yang M; Sun T; Wang L; Yu D; Zhang X; Miao X; Liu J; Zhao D; Li H; Tan W; Lin D
Clin Cancer Res; 2008 May; 14(10):3230-6. PubMed ID: 18483392
[TBL] [Abstract][Full Text] [Related]
29. Novel polymorphisms in caspase-8 are associated with breast cancer risk in the California Teachers Study.
Park HL; Ziogas A; Chang J; Desai B; Bessonova L; Garner C; Lee E; Neuhausen SL; Wang SS; Ma H; Clague J; Reynolds P; Lacey JV; Bernstein L; Anton-Culver H
BMC Cancer; 2016 Jan; 16():14. PubMed ID: 26758508
[TBL] [Abstract][Full Text] [Related]
30. The Apoptosis Pathway and CASP8 Variants Conferring Risk for Acute and Overuse Musculoskeletal Injuries.
Seale K; Burger M; Posthumus M; Häger CK; Stattin E; Nilsson KG; Collins M; September AV
J Orthop Res; 2020 Mar; 38(3):680-688. PubMed ID: 31692049
[TBL] [Abstract][Full Text] [Related]
31. Fine-mapping CASP8 risk variants in breast cancer.
Camp NJ; Parry M; Knight S; Abo R; Elliott G; Rigas SH; Balasubramanian SP; Reed MW; McBurney H; Latif A; Newman WG; Cannon-Albright LA; Evans DG; Cox A
Cancer Epidemiol Biomarkers Prev; 2012 Jan; 21(1):176-81. PubMed ID: 22056502
[TBL] [Abstract][Full Text] [Related]
32. An updated meta-analysis of the association between fibroblast growth factor receptor 4 polymorphisms and susceptibility to cancer.
Moazeni-Roodi A; Sarabandi S; Karami S; Hashemi M; Ghavami S
Biosci Rep; 2020 Oct; 40(10):. PubMed ID: 33017009
[TBL] [Abstract][Full Text] [Related]
33. Genetic polymorphisms of the CASP8 gene promoter may not be associated with colorectal cancer in Han Chinese from southwest China.
Xiao MS; Chang L; Li WL; Du YS; Pan Y; Zhang DF; Wen Y; Luo J; Li XY; Yao YG
PLoS One; 2013; 8(7):e67577. PubMed ID: 23844036
[TBL] [Abstract][Full Text] [Related]
34. A six-nucleotide insertion-deletion polymorphism in the CASP8 promoter is associated with susceptibility to multiple cancers.
Sun T; Gao Y; Tan W; Ma S; Shi Y; Yao J; Guo Y; Yang M; Zhang X; Zhang Q; Zeng C; Lin D
Nat Genet; 2007 May; 39(5):605-13. PubMed ID: 17450141
[TBL] [Abstract][Full Text] [Related]
35. [Clinical and Functional Importance of Selected CASP8 and CASP9 Polymorphisms in Breast Carcinoma].
Brynychová V; Václavíková R; Kubáčková K; Mrhalová M; Kodet R; Rauš K; Vrána D; Gatěk J; Bendová M; Souček P
Klin Onkol; 2016; 29(6):445-453. PubMed ID: 27951722
[TBL] [Abstract][Full Text] [Related]
36. Caspase polymorphisms and genetic susceptibility to multiple myeloma.
Hosgood HD; Baris D; Zhang Y; Zhu Y; Zheng T; Yeager M; Welch R; Zahm S; Chanock S; Rothman N; Lan Q
Hematol Oncol; 2008 Sep; 26(3):148-51. PubMed ID: 18381704
[TBL] [Abstract][Full Text] [Related]
37. A meta-analysis of caspase-8 -652 6N del polymorphism and digestive tract cancer risk.
Du H; Song GX; Fang MZ; Shu YQ; Zhao X; Zhu LJ
J Biomed Res; 2019 Jun; 33(3):173-180. PubMed ID: 30057371
[TBL] [Abstract][Full Text] [Related]
38. CASP8 promoter polymorphism is associated with high-risk HPV types and abnormal cytology but not with cervical cancer.
Chatterjee K; Williamson AL; Hoffman M; Dandara C
J Med Virol; 2011 Apr; 83(4):630-6. PubMed ID: 21328377
[TBL] [Abstract][Full Text] [Related]
39.
Cai J; Ye Q; Luo S; Zhuang Z; He K; Zhuo ZJ; Wan X; Cheng J
Oncotarget; 2017 Aug; 8(34):56780-56790. PubMed ID: 28915630
[TBL] [Abstract][Full Text] [Related]
40. A six-nucleotide deletion polymorphism in the casp8 promoter is associated with reduced risk of esophageal and gastric cancers in Kashmir valley.
Malik MA; Zargar SA; Mittal B
Indian J Hum Genet; 2011 Sep; 17(3):152-6. PubMed ID: 22345985
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
